Pharmacokinetics of recombinant factor VIII in adults with severe hemophilia A: fixed-sequence single-dose study of octocog alfa, rurioctocog alfa pegol, and efanesoctocog alfa

[1]  J. Oldenburg,et al.  Efanesoctocog Alfa Prophylaxis for Patients with Severe Hemophilia A. , 2023, The New England journal of medicine.

[2]  J. Johnsen,et al.  Heterogeneity in the half-life of factor VIII concentrate in patients with hemophilia A is due to variability in the clearance of endogenous von Willebrand factor. , 2023, Journal of thrombosis and haemostasis : JTH.

[3]  T. Lissitchkov,et al.  Efanesoctocog alfa for hemophilia A: results from a phase 1 repeat-dose study , 2021, Blood advances.

[4]  J. Dumont,et al.  Efanesoctocog Alfa Half-Life and Clearance Are Independent of von Willebrand Factor in Severe Hemophilia A: A Post Hoc Analysis from Phase 1/2a Studies , 2021, Blood.

[5]  C. Hermans,et al.  Living with a “hemophilia‐free mind” – The new ambition of hemophilia care? , 2021, Research and practice in thrombosis and haemostasis.

[6]  F. Peyvandi,et al.  Hemophilic arthropathy: Current knowledge and future perspectives , 2021, Journal of thrombosis and haemostasis : JTH.

[7]  J. Thachil,et al.  Asymptomatic Joint Bleeding and Joint Health in Hemophilia: A Review of Variables, Methods, and Biomarkers , 2021, Journal of blood medicine.

[8]  D. Quon,et al.  BIVV001 Fusion Protein as Factor VIII Replacement Therapy for Hemophilia A. , 2020, The New England journal of medicine.

[9]  E. Santagostino,et al.  WFH Guidelines for the Management of Hemophilia, 3rd edition , 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

[10]  J. Johnsen,et al.  Biological mechanisms underlying inter‐individual variation in factor VIII clearance in haemophilia , 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

[11]  M. Recht,et al.  Young adult outcomes of childhood prophylaxis for severe hemophilia A: results of the Joint Outcome Continuation Study. , 2020, Blood advances.

[12]  Terrence M. Dobrowsky,et al.  BIVV001, a new class of factor VIII replacement for hemophilia A that is independent of von Willebrand factor in primates and mice , 2020 .

[13]  G. Dolan,et al.  Achieving the unimaginable: Health equity in haemophilia , 2019, Haemophilia : the official journal of the World Federation of Hemophilia.

[14]  V. Blanchette,et al.  Genetic determinants of VWF clearance and FVIII-binding modify FVIII pharmacokinetics in pediatric hemophilia A patients. , 2019, Blood.

[15]  M. Karlsson,et al.  Relationship between factor VIII activity, bleeds and individual characteristics in severe hemophilia A patients , 2019, Haematologica.

[16]  C. Hermans,et al.  Practical aspects of extended half-life products for the treatment of haemophilia , 2018, Therapeutic advances in hematology.

[17]  P. Lenting,et al.  Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A. , 2016, Blood.

[18]  B. Konkle,et al.  Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A. , 2015, Blood.

[19]  E. Berntorp,et al.  Methods for individualising factor VIII dosing in prophylaxis , 2014, European journal of haematology. Supplementum.

[20]  M. Reding,et al.  Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A , 2014, Journal of thrombosis and haemostasis : JTH.

[21]  J. Dumont,et al.  Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. , 2014, Blood.

[22]  D. Viuff,et al.  Enhancing the pharmacokinetic properties of recombinant factor VIII: first‐in‐human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A , 2013, Journal of thrombosis and haemostasis : JTH.

[23]  K. Kurnik,et al.  Identification and long‐term observation of early joint damage by magnetic resonance imaging in clinically asymptomatic joints in patients with haemophilia A or B despite prophylaxis , 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

[24]  F. Rosendaal,et al.  Analysis of low frequency bleeding data: the association of joint bleeds according to baseline FVIII activity levels , 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

[25]  E G Tuddenham,et al.  The hemophilias--from royal genes to gene therapy. , 2001, The New England journal of medicine.